

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

## Viread (tenofovir disoproxil fumarate)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Viread (tenofovir disoproxil fumarate)	May be subject to quantity limit

**\*\*DC Medicaid – HIV therapy is carved out**

### **APPROVAL CRITERIA**

Requests for Viread (tenofovir disoproxil fumarate) may be approved for individuals who meet the following criteria:

- I. Individual is 2 years of age or older; **AND**
- II. Individual has a diagnosis of chronic Hepatitis B infection;

**OR**

- III. Individual is 2 years of age and older; **AND**
- IV. Individual has a diagnosis of HIV-1 infection; **AND**
- V. Individual is using in combination therapy with other antiretroviral agents;

**OR**

- VI. Individual is using as prophylaxis for hepatitis B reactivation in the setting of immune suppression or in combination with hepatitis C direct-acting antiviral therapy (AASLD 2018);

**OR**

- VII. Individual is a solid organ transplant recipient and using as prophylaxis for hepatitis B reactivation (AASLD 2018).

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

**Note:** Viread (tenofovir disoproxil fumarate) has black box warnings for severe exacerbations of hepatitis with drug discontinuation. Hepatic function should be monitored for several months after discontinuation of therapy to assess for severe exacerbation of hepatitis.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
District of Colombia	10/1/2017	Viread is only covered for Hepatitis B. HIV is carved out; claim should be billed to Fee For Service (FFS).

**Key References:**

1. Terrault NA, Lok A, McMahon BJ, et al. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. *Hepatology*. 2018; 67:1560-99.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 27, 2019.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
5. Drug Facts and Comparisons. Facts and Comparisons [database online]. St. Louis, MO: Wolters Kluwer Health, Inc; 2019. Updated periodically.
6. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.